There aren't many all comer trials because not many companies are developing drugs that work in all cancer types these days. Even Keytruda is tied to PD-1 expression as a biomarker.
RAC really is an unusual company with a very unusual drug. You really need to build your valuation bottom up from first principles. Imagine what doxorubicin would be worth if it had only been discovered a couple of years ago and had more than 15 years of patent protection left.
There aren't many all comer trials because not many companies...
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.42 |
Change
-0.045(3.07%) |
Mkt cap ! $244.6M | |||
| Open | High | Low | Value | Volume |
| $1.49 | $1.49 | $1.41 | $238.0K | 164.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 2011 | 1 |
View Market Depth
| Last trade - 15.55pm 14/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |